REGEND 003
Alternative Names: REGEND-003Latest Information Update: 27 Jan 2023
At a glance
- Originator Regend Therapeutics
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetic nephropathies; Renal transplant rejection
Most Recent Events
- 20 Dec 2022 Preclinical trials in Diabetic nephropathies in China (Parenteral), prior to December 2022 (Regend Therapeutics pipeline, December 2022).
- 20 Dec 2022 Preclinical trials in Renal transplant rejection in China (Parenteral), prior to December 2022 (Regend Therapeutics pipeline, December 2022).
- 20 Dec 2022 Regend Therapeutics plans a phase I clinical trial in 2023 (Regend Therapeutics pipeline, December 2022)